CDX-1140 Clinical Trials
2 recruitingBiologic
Phase 12Phase 21
Showing 1–2 of 2 trials
Recruiting
Phase 1Phase 2
A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC)
Biliary CancerBile Duct CancerCancer of the Bile Duct
National Cancer Institute (NCI)60 enrolled1 locationNCT05849480
Recruiting
Phase 1
CD40 Agonist, Flt3 Ligand, and Chemotherapy in HER2 Negative Breast Cancer
Metastatic Breast CancerHER2-negative Breast Cancer
University of Texas Southwestern Medical Center30 enrolled7 locationsNCT05029999